BofA lowered the firm’s price target on GoodRx (GDRX) to $4.25 from $4.50 and keeps an Underperform rating on the shares after the company ...

GoodRx (NASDAQ:GDRX – Free Report) had its price objective reduced by Citigroup from $7.00 to $6.25 in a research note issued ...

GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco.

KeyBanc lowered the firm’s price target on GoodRx (GDRX) to $6 from $7 and keeps an Overweight rating on the shares. The firm notes healthcare ...

GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) dropped 8.4% during trading on Monday after Citigroup lowered their price target on the stock from $7.00 to $6.25. Citigroup currently has a buy ...

Analysts have set 12-month price targets for GoodRx Holdings, revealing an average target of $6.25, a high estimate of $7.00, and a low estimate of $6.00. Highlighting a 26.47% decrease, the current ...

In my view, there are now enough positives to balance out the ongoing risks for GoodRx, especially at its lower share price. Investors can consider a small trial position here. GoodRx's revenue ...

Prices for insulin, the essential drug for treating diabetes, have plummetted to their lowest levels in a decade following a ...

Goodrx Holdings Inc (GDRX) stock saw a modest uptick, ending the day at $4.57 which represents a slight increase of $0.15 or 3.39% from the prior close of $4.42. The stock opened at $4.41 and touched ...

The average price per insulin unit hit a 10-year low in 2024, largely driven by federal actions and voluntary price cuts from drugmakers, according to a Jan. 15 GoodRx report.

GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today announced a new GoodRx for Pets ...

At the 2025 JP Morgan Healthcare Conference, GoodRx’s recently appointed CEO Wendy Barnes highlighted the company’s strategic position to address the gaps in the US healthcare landscape.